"Inadequate Response": Suboptimal, Treatment Resistance, and Pseudo Resistance in Individuals with MDD

Published: July 21, 2023, 4 a.m.

Host: Denise Vanacore, PhD, FNP-BC, PMHNP-BC
\n\n\n \n

Many patients with Major Depressive Disorder (MDD) do not adequately respond to or fail first-line antidepressant therapy causing significant setbacks in patient care and dramatic decreases in QoL. The lack of agreement on approaching the next treatment step creates a significant gap, leading to suboptimally treated MDD. Clinicians have the option to augment therapy or switch to another class of antidepressants to improve the management of a patient\u2019s residual symptoms of MDD. This program will help highlight the appropriate treatment for individuals with MDD who are suboptimally treated and provide evidence-based best practices related to making a timely switch from a first-line to a second-line antidepressant or augmenting the current treatment option.